How to Get Lantus (Insulin Glargine) in North Carolina

What Is Lantus and Why Is It Prescribed?

Lantus is the brand name for insulin glargine 100 units/mL, a recombinant human insulin analog that provides up to 24 hours of basal insulin coverage with no pronounced peak. The FDA approved Lantus in April 2000 for adults with type 1 or type 2 diabetes, and extended that indication to pediatric patients (age 6 and older with type 1 diabetes) in subsequent label updates [1]. Insulin glargine achieves its flat, prolonged action by precipitating at physiologic pH after subcutaneous injection, creating a slow-release depot.

The landmark ORIGIN trial (N=12,537) compared insulin glargine to standard care in people with dysglycemia and cardiovascular risk. After a median follow-up of 6.2 years, the glargine group achieved a median HbA1c of 6.2% versus 6.5% in the standard-care group, with no increase in cardiovascular mortality (hazard ratio 1.02 to 95% CI 0.94 to 1.11; P<0.001 for non-inferiority) [2]. That finding gave clinicians confidence that long-term use of basal insulin does not raise cardiac risk, which matters for the large population of North Carolinians with both diabetes and heart disease.

The American Diabetes Association 2024 Standards of Care list basal insulin as a first injectable option when oral agents and GLP-1 receptor agonists are insufficient to reach glycemic targets, or when HbA1c exceeds 10 to 11% at diagnosis [3]. North Carolina has approximately 1.1 million adults with diagnosed diabetes, or about 11.2% of the adult population, according to CDC surveillance data [4]. That prevalence means Lantus access questions arise daily across the state, from Asheville to Wilmington.

Insulin glargine is available in two concentrations: U-100 (Lantus, 10 mL vial or 3 mL SoloStar pen) and U-300 (Toujeo). These are not interchangeable unit-for-unit; a provider must specify which concentration on the prescription [5].

Who Can Prescribe Lantus in North Carolina?

Any licensed prescriber with DEA registration can write a Lantus prescription in North Carolina. Physicians (MD and DO), nurse practitioners (NP), and physician assistants (PA) all have full prescribing authority for insulin glargine under North Carolina law.

North Carolina General Statute 90-18.2 grants full independent prescriptive authority to NPs who hold a Certificate of Prescriptive Authority from the North Carolina Board of Nursing [6]. This means NPs practicing in telehealth platforms, federally qualified health centers, or independent specialty clinics can prescribe Lantus without a supervising physician co-signing. PAs prescribe under a supervising or collaborating physician agreement per NC GS 90-18.1 [7], but in practice the PA writes and signs the prescription directly. Clinical pharmacists with a collaborative practice agreement (CPA) can also adjust insulin doses, though they typically do not issue the initial prescription independently.

The practical takeaway: if you are seen in a North Carolina telehealth visit, an NP on that platform can prescribe Lantus legally without any additional physician sign-off, so long as the NP holds an active NC prescriptive authority certificate.

Telehealth Prescribing of Lantus in North Carolina

Telehealth is a fully legal pathway to a Lantus prescription in North Carolina. The state's telehealth parity law (NC GS 58-3-295) requires commercial insurers to cover telehealth visits at the same rate as in-person visits, which significantly lowers out-of-pocket cost for patients who have private insurance [8]. State law does not require an initial in-person visit before a provider can prescribe a chronic-disease medication like insulin glargine via telehealth, as long as the provider establishes a valid provider-patient relationship during the synchronous video encounter.

A 2022 review in JAMA Internal Medicine found that telehealth diabetes management programs reduced HbA1c by a mean of 0.5 percentage points compared to usual care in randomized controlled trials, with the greatest benefit in patients who had baseline HbA1c above 8% [9]. That evidence base supports using telehealth not just for prescription access, but for ongoing insulin titration and glucose management.

For a Lantus prescription via telehealth in North Carolina, a typical visit covers: current glucose logs or continuous glucose monitor (CGM) data, current HbA1c result (within the past 90 days is standard), current medications, kidney function (serum creatinine and eGFR), and hypoglycemia history. The visit usually takes 20 to 40 minutes. After the visit, most telehealth platforms send the prescription electronically to any North Carolina retail or mail-order pharmacy within two to four hours.

The HealthRX clinical team uses the following four-step telehealth-to-pharmacy pathway for North Carolina patients seeking Lantus:

1. Upload a recent HbA1c result (within 90 days) and a 7-day glucose log before the visit.
2. Complete a 20-minute synchronous video consultation with a licensed NC prescriber.
3. Receive the electronic prescription at your chosen North Carolina pharmacy.
4. Confirm prior authorization status with the pharmacy before pickup, especially if you are on a state Medicaid or commercial plan requiring step therapy.

Labs Required Before Starting Lantus in North Carolina

Before a provider issues a Lantus prescription, they need enough clinical data to dose safely and to satisfy insurance documentation requirements. The minimum lab set is: fasting plasma glucose, HbA1c, basic metabolic panel (including serum creatinine and eGFR for renal dose considerations), and weight or BMI.

The FDA Lantus prescribing label specifies that dose adjustments are necessary in patients with renal impairment because insulin clearance may be reduced, increasing hypoglycemia risk [5]. A serum creatinine or eGFR drawn within 90 days satisfies that requirement. Most North Carolina commercial plans and NC Medicaid also require a documented HbA1c above a threshold (typically above 7% for type 2 diabetes) before approving Lantus under a prior authorization protocol.

Additional labs that many endocrinologists order for type 1 diabetes or new-onset insulin-requiring diabetes include: C-peptide (to confirm endogenous insulin secretory capacity), fasting lipid panel, and thyroid-stimulating hormone (TSH). These are not required to prescribe, but they provide a complete metabolic picture and are often required by NC Medicaid for type 1 diabetes classification [10].

A point-of-care HbA1c drawn during a telehealth-adjacent lab visit (LabCorp or Quest locations are available across North Carolina) takes one business day to result and satisfies most prior authorization lab requirements.

How to Fill a Lantus Prescription at a North Carolina Pharmacy

Once you have a prescription, you can fill it at any North Carolina licensed retail pharmacy or through a licensed mail-order pharmacy shipping into NC. Major chains including CVS, Walgreens, Walmart Pharmacy, and Costco Pharmacy all stock Lantus U-100 vials and SoloStar pens. Independent compounding pharmacies operating under 503A state licensure can also dispense insulin glargine for patient-specific prescriptions, though they cannot manufacture it in bulk for general distribution.

Walmart sells ReliOn brand NovoLog (insulin aspart) over the counter, but Lantus specifically requires a prescription in North Carolina; it is not among the OTC insulins currently available without a script in the state [11]. Patients seeking lower out-of-pocket cost should ask the pharmacist about biosimilar substitution. FDA-approved insulin glargine biosimilars include Basaglar (Eli Lilly), Semglee (Viatris), and Rezvoglar (Eli Lilly). Semglee received FDA interchangeable biosimilar designation in July 2021, which means North Carolina pharmacists can substitute Semglee for Lantus without contacting the prescriber, unless the prescriber writes "brand medically necessary" [12].

Cash prices for Lantus 10 mL vial at North Carolina pharmacies range from approximately $280 to $320 without insurance. Semglee cash price runs approximately $98 to $120 for the same quantity, representing a 60 to 65% reduction. GoodRx and similar discount programs can further reduce prices at specific pharmacy locations.

For mail-order, most pharmacy benefit managers (PBMs) process a 90-day supply in three to seven business days from receipt of an electronic prescription. Expedited shipping options exist for patients who have exhausted their current supply.

Prior Authorization Requirements in North Carolina

Prior authorization (PA) is the main administrative barrier to Lantus access in North Carolina. Both commercial plans and NC Medicaid require documentation before approving insulin glargine coverage.

NC Medicaid covers insulin glargine for type 1 diabetes without a step-therapy requirement in most cases. For type 2 diabetes, NC Medicaid requires documented trial and inadequate response to at least one preferred formulary insulin (typically NPH or regular insulin) before approving Lantus, along with an HbA1c above 8% and a recent clinic visit note [13]. The NC Medicaid Clinical Coverage Policy 9-x covers antidiabetic agents and is publicly available from the NC Division of Health Benefits.

Commercial insurance PA criteria vary by plan but typically require: HbA1c documentation, prescriber attestation that a biosimilar or preferred formulary insulin was tried or is contraindicated, and a diagnosis code (E10.x for type 1, E11.x for type 2). Most commercial insurers in North Carolina process PA requests within three to five business days. Expedited PA requests for urgent clinical situations (e.g., new type 1 diabetes diagnosis, DKA recovery) must be processed within 24 to 72 hours under NC insurance law.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines state: "Basal insulin analogues such as insulin glargine or insulin detemir are preferred over NPH insulin due to lower risk of nocturnal hypoglycemia and less weight gain" [14]. That guideline language can be used verbatim in a PA appeal letter when a North Carolina insurer requires step therapy through NPH.

Transferring an Existing Lantus Prescription to North Carolina

Patients moving to North Carolina from another state can transfer a Lantus prescription to a North Carolina pharmacy. Federal law permits one transfer of a non-controlled prescription between licensed pharmacies across state lines [15]. Because insulin glargine is not a controlled substance, the transfer can happen directly: call your current pharmacy, ask them to fax or electronically transfer the prescription to your chosen North Carolina pharmacy, and pick it up once the transfer is confirmed.

If the original prescription has no refills remaining, the transfer pharmacy in North Carolina can contact your out-of-state prescriber for a new prescription. Alternatively, a North Carolina telehealth visit can generate a fresh prescription immediately, bypassing the transfer process entirely. For patients whose out-of-state prescriber is not licensed in NC, a new prescription from a NC-licensed provider is the correct path.

Cost Assistance Programs for Lantus in North Carolina

Uninsured and underinsured North Carolina residents have several cost-reduction options.

Sanofi's Insulins Valyou Savings Program caps out-of-pocket cost at $99 per month for up to 10 boxes of Lantus SoloStar pens or 2 vials of Lantus for eligible patients [16]. Eligibility is based on income (below 600% of federal poverty level) and residency in the United States. Applications are submitted online or by phone.

The federal Low Income Subsidy (LIS, also called Extra Help) under Medicare Part D reduces insulin copays to $35 per month for eligible beneficiaries. The Inflation Reduction Act of 2022 capped Medicare Part D insulin cost-sharing at $35 per month beginning January 2023, which directly benefits North Carolina Medicare enrollees who use Lantus [17].

The North Carolina Navigator and Assisters program, run through the NC Department of Insurance, can help residents enroll in ACA marketplace plans that cover Lantus under standard formulary or specialty tiers. Many marketplace silver-tier plans in NC include at least one basal insulin at preferred formulary cost-sharing after deductible.

NC Medicaid expansion under the Affordable Care Act took effect December 1, 2023, adding approximately 600,000 previously uninsured adults to Medicaid eligibility. Newly enrolled adults with diabetes can access insulin glargine through NC Medicaid Preferred Drug List coverage, subject to the PA requirements described above [18].

Dosing and Administration of Insulin Glargine

Insulin glargine is injected subcutaneously once daily at the same time each day. The FDA-approved label recommends starting at 0.2 units/kg/day in insulin-naive type 2 diabetes patients, with titration every three to seven days based on fasting plasma glucose targets [5]. The ADA 2024 Standards of Care recommend a fasting glucose target of 80 to 130 mg/dL for most non-pregnant adults [3].

The BRIGHT trial (N=929) compared insulin glargine U-300 (Toujeo) to insulin degludec (Tresiba) in insulin-naive type 2 diabetes patients and found both agents reduced HbA1c by approximately 1.6 percentage points at 24 weeks, with similar rates of confirmed hypoglycemia [19]. While that trial compared next-generation basal insulins rather than standard Lantus U-100, it reinforces the principle that consistent once-daily dosing and structured titration, rather than the specific product, drive most of the glycemic benefit.

Common injection sites are the abdomen (fastest absorption), thigh, and upper arm. Lantus must not be mixed in the same syringe with any other insulin, as the acidic pH of glargine can alter the action profile of rapid-acting insulins [5]. Patients switching from twice-daily NPH to once-daily insulin glargine typically require a 20% dose reduction at initiation to account for the more predictable absorption and reduced hypoglycemia risk of the analog.

Monitoring After Starting Lantus in North Carolina

After initiation, fasting blood glucose should be checked daily and the dose titrated by 2 units every three days until fasting glucose consistently falls between 80 and 130 mg/dL, following the treat-to-target protocol validated in multiple basal insulin titration trials [20]. HbA1c should be rechecked at three months to confirm glycemic response.

Hypoglycemia is the primary safety concern. The ORIGIN trial recorded a rate of 1.00 severe hypoglycemic event per 100 patient-years in the glargine group, compared to 0.31 per 100 patient-years in standard care [2]. Patients should keep fast-acting glucose (15 to 20 g of glucose tablets or juice) accessible at all times and wear medical ID identifying themselves as insulin users.

North Carolina providers using CGM for insulin-managed patients should target a time-in-range (70 to 180 mg/dL) above 70%, per the 2023 International Consensus on Time in Range [21]. CGM data uploads can be shared with telehealth providers before visits, reducing the need for in-office glucose meter downloads and supporting fully remote Lantus titration.

Kidney function should be rechecked every 6 to 12 months in patients with established chronic kidney disease (CKD stages 3 to 5), as progressive renal impairment reduces insulin clearance and may require dose reduction to prevent hypoglycemia [5].